FOR: CARDIOCOMM SOLUTIONS, INC.
TSX VENTURE SYMBOL: EKG
October 23, 2013
Interest grows as select pharmacies carry the HeartCheck™ PEN for sale in Ontario
TORONTO, ONTARIO – CardioComm Solutions, Inc. (“CardioComm Solutions” or the “Company”) (TSX VENTURE: EKG) today announced that Remedy’sRx pharmacies have joined the Company’s campaign to promote awareness of the HeartCheck™ PEN. Select pharmacies in more Ontario cities will now be carrying the HeartCheck™ PEN for sale to consumers. Remedy’sRx will be recognized in the CardioComm Solutions HeartCheck™ PEN television commercial that is airing on the CBC television network until the end of October.
“The addition of Remedy’sRx to our distribution network is an indication that acceptance of the HeartCheck™ PEN and SMART Monitoring technologies continues to grow. While head office support is first required, the decision for a pharmacy to participate in the “Take Control” campaign requires independent agreement from each pharmacy location. Pharmacists are interested in introducing the new health monitoring benefits that the use of the HeartCheck™ PEN can offer to their patients. Additionally, pharmacists have expressed interest in learning more about offering in-pharmacy electrocardiogram (“ECG”) screening services for arrhythmia detection. This move would be complementary and supportive of existing pharmacy based MedsCheck services,” said Etienne Grima, CEO of CardioComm Solutions. “The Remedy’sRx pharmacy banner group is a large chain with over 110 pharmacies in Ontario alone, and we look forward to continued opportunities in taking this initiative to their pharmacy members across Canada,” added Mr. Grima.
CardioComm Solutions launched the “Take Control” campaign to target the 40+ year old market and to encourage these consumers to monitor their heart health using ECG recordings for arrhythmia detection. Last week during the Canadian Cardiovascular Congress/Vascular 2013 scientific meeting, data was presented showing that use of manual pulse check was not appropriate for detection of irregular heart rates such as is seen with atrial fibrillation. This latest evidence offers further validation for use of the HeartCheck™ devices and the SMART Monitoring ECG service heart rhythm monitoring and arrhythmia detection/identification.
“We are encouraged by the interest from pharmacists and look forward to the implementation of a pharmacy-based sales strategy for both the HeartCheck™ PEN ECG devices as well as the SMART Monitoring ECG service under our Partner Program initiative. Plans are now underway to continue the push into additional pharmacy banner groups not only in Ontario but across Canada and in the United States as well,” said Simi Grosman, member of the Board of Directors for the Company.
About CardioComm Solutions
CardioComm Solutions’ patented and proprietary technology is used in products for recording, viewing, analyzing and storing electrocardiograms (ECGs) for diagnosis and management of cardiac patients. Products are sold worldwide through a combination of an external distribution network and a North American-based sales team. The Company has earned the ISO 13485 certification, is HPB approved, HIPAA compliant, and has received FDA market clearance for its software devices. CardioComm Solutions, Inc. is headquartered in Toronto, Canada, with offices in Victoria, B.C.
For Further Information On Cardiocomm Solutions Please Contact:
Etienne Grima, Chief Executive Officer
This release may contain certain forward-looking statements with respect to the financial condition, results of operations and business of CardioComm Solutions and certain of the plans and objectives of CardioComm Solutions with respect to these items. By their nature, forward-looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release